Skip to main content
. 2022 Jan 13;107(9):2108–2120. doi: 10.3324/haematol.2021.279012

Figure 2.

Figure 2.

Progression-free survival per investigator assessment in the high-risk population of patients with del(17p), del(11q), TP53 mutations, and/or unmutated IGHV. CI: confidence interval; mo: months; NE: not estimable; PFS: progression-free survival.